Promising new ovarian cancer treatment could soon be available on the NHS

Ovarian Cancer Action | June 2018 |Promising new ovarian cancer treatment could soon be available on the NHS

The National Institute for Health and Care Excellence (NICE) has issued draft guidance on a promising new ovarian cancer drug, niraparib, advising that it is a suitable candidate for use in the Cancer Drugs Fund (CDF) (Ovarian Cancer Action). 

Ovarian cancer is the fifth most common cause of cancer death in women and has the highest mortality rate of all gynaecological cancers. Five-year survival in England and Wales is also among the lowest in Europe – well below the European average. While these figures are bleak, it is exciting to think that niraparib could provide a much-needed new option for many women with the disease.

drug-1674890_1280

“We are pleased that the NICE committee has recognised the high unmet need in ovarian cancer treatment,” said Katherine Taylor, Chief Executive of Ovarian Cancer Action. “Every day matters for patients and their families and we hope that the CDF submission is successful and will deliver access to many women in England and Wales as soon as possible. We also look forward to a review by the Scottish Medicines Consortium (SMC) later this year.”

Source: Ovarian Cancer Action

Related:

NICE Niraparib for ovarian cancer [ID1041]

In the media:

The Independent Ovarian cancer ‘game changer’ drug which holds back disease’s return gets first NHS fund approval

Sky News Niraparib drug: Daily pill available on NHS for first time is ‘milestone’ in ovarian cancer treatment

Express Ovarian cancer – ‘game changing’ new drug puts patient’s tumour into remission

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s